share_log

SELLAS Life Sciences Announced Review Of Ongoing Phase 3 REGAL Clinical Trial Of Galinpepimut-S In Acute Myeloid Leukemia By IDMC

Benzinga ·  Jun 17 21:07

– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications –

– No Safety or Futility Concerns Were Raised Based on the Efficacy and Safety Assessment of All REGAL Patients –

– Interim Analysis Anticipated by Q4 2024 –

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment